Table 2.
Conversion ratios reported by clinical studies and observational studies
| Author(s) | Study design | Number of subjects | Conversion ratio | Journal | Year of publication |
|---|---|---|---|---|---|
| Bruera E (12) | Retrospective | 733 | 1:5.33a | Cancer | 1996 |
| Lawlor P (13) | Retrospective | 207 | 1:5.76a | Pain | 1997 |
| Moriarty M (17) | Blinded, crossover | 100 | 1:7.5 | J Clin Res | 1999 |
| Palangio M (14) | Multicenter, joint, open-label | 445 | 1:5 | J Pain Symptom Manage | 2002 |
| Weinstein SM (18) | Multicenter, joint, open-label | 343 | 1:8 | Clin Ther | 2006 |
| Wirz S (16) | Prospective observational | 50 | 1:5 | Clin J Pain | 2006 |
| Wallace M (15) | Multicenter, joint, open-label | 148 | 1:5 | J Int Med Res | 2008 |
aConversion ratio converted by the actual dose.